A US neuroscientist claims that some of the studies of the experimental agent, Simufilam, a drug that targets amyloid beta in Alzheimer’s disease, are flawed and has taken his concerns to the NIH. Medscape Medical News…Read More
Comments are closed.
Type above and press Enter to search. Press Esc to cancel.